C3N-02145
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 68.40793977
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.400
- HEDGEHOG_SIGNALING+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- PROTEIN_SECRETION+0.330
- PANCREAS_BETA_CELLS+0.240
- UV_RESPONSE_DN+0.180
- NOTCH_SIGNALING+0.160
- ANGIOGENESIS+0.150
- WNT_BETA_CATENIN_SIGNALING+0.150
- COAGULATION+0.120
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.550
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.390
- MYC_TARGETS_V1-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
- INFLAMMATORY_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-01409 | — | cohortA1 | 0.876 |
| 2 | C3L-02165 | — | cohortA2 | 0.857 |
| 3 | 65f86d9a-828b-4e8b-a656-38baba5a54f7 | — | — | 0.855 |
| 4 | C3L-02834 | — | cohortA1 | 0.850 |
| 5 | SRR25617864 | — | A | 0.849 |
| 6 | SRR8518225 | — | B | 0.844 |
| 7 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.842 |
| 8 | sclcCHTN02019_S70.txt | — | cohortSC | 0.840 |
| 9 | 8a25dfb0-edd0-4a44-9a6b-8f3f761b940c | — | — | 0.840 |
| 10 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |